Bladder cancer is a heterogeneous disease that carries a significant risk of progression and lethality. Radical cystectomy with pelvic lymph node dissection remains the predominant treatment for patients with muscle-invasive disease and offers the best chance of long-term disease control. However, radical surgery is insufficient in patients with advanced-stage disease. Current staging techniques are limited in their ability to detect extravesical disease and lymph node metastases. Thus, integration of systemic therapy with surgery to potentially eradicate micrometastases provides survival superior to that with surgery alone. Yet, because bladder cancer is typically a disease that affects an elderly population of patients with multiple comorbidities, there is a need for less invasive and bladder-conserving therapies. Some physicians have attempted to minimize morbidity by pursuing minimally invasive surgical techniques; however, the long-term effectiveness of this approach remains unproven. Trimodality therapy could be considered in patients with favorable disease status, and may be offered as a reasonable alternative, but does not replace standard treatments for patients with more aggressive disease. Consequently, further improvements in outcomes will rely on improved patient selection based on clinical and molecular assessments.
Bladder cancer remains the fourth most common cancer in men and consistently falls within the top 10 most common cancers in women. Additionally, in the United States, it is one of the most expensive cancers to treat, costing the government an estimated $3.7 billion per year, mainly because of the rigorous follow-up needed to detect recurrent disease. Initially, the majority of patients are diagnosed with localized disease (20% of which is muscle-invasive), with only 8% and 4% of patients having locally advanced and metastatic disease, respectively. Radical surgery is the predominant treatment for those who present with de novo muscle-invasive bladder cancer (MIBC) and those with non–muscle-invasive disease that progresses after intravesical therapy. However, because bladder cancer typically affects an elderly population (with a median age of 73 years at diagnosis), there is a need for less invasive and bladder-conserving therapies.
Radical cystectomy (RC) involves removal of the bladder and seminal vesicles en bloc in males, and removal of the bladder, uterus, fallopian tubes, ovaries, and a segment of the anterior vaginal wall in females. Bowel is commonly utilized for reconstructive purposes to store and empty the urine. RC typically involves an operation lasting between 4 and 10 hours and a hospital stay ranging between 5 and 10 days. Postoperative complications are common and include atelectasis, wound infection, and ileus, plus the complications of prolonged anesthesia that occur in an elderly population, most of whom have pre-existing coronary and pulmonary disease.
Current surgical techniques have been in evolution for the last 40 years. Early results indicated that only about 50% of patients were cured with surgery, and most patients died of metastatic disease within 3 years of diagnosis. During the 1970s, various preoperative radiation regimens were employed, but these failed to show convincing evidence of benefit. The main limitation of RC was the considerable associated morbidity. However, surgical techniques have significantly improved over time, and the procedure has become much more accepted, particularly since the implementation of orthotopic urinary diversions (ie, neobladders).
Now RC with pelvic lymph node dissection is considered the gold standard of treatment for MIBC and offers the best chance of long-term disease control. However, survival is closely associated with pathologic stage, and unfortunately, clinical staging diverges from pathologic staging in around 50% of cases. Consequently, there is obviously a great need for better determinants of stage. Molecular markers are in the forefront of research in this area, with many groups trying to identify gene signatures for each pathologic feature.
Lymph node dissection
A well-performed lymphadenectomy is an essential component of RC. Not only is the removal of lymph nodes prognostic, as in most other cancers, but the extent of dissection has an impact on outcome.[6,7] A “standard” lymph node dissection involves removal of all tissue within the boundaries of the genitofemoral nerve laterally, the bladder medially, the circumflex iliac vein inferiorly (lymph node of Cloquet), the bifurcation of the common iliac artery superiorly, and hypogastric vessels posteriorly. Lymph node packets are typically removed from regions around the external iliac, internal iliac, and obturator vessels, but recent mapping studies have more accurately described the common landing zones for nodal metastases. An “extended” lymph node dissection is carried up to the aortic bifurcation and includes presacral nodes. There is no exact consensus on the minimum number of lymph nodes that must be removed for success, but early reports suggested that at least nine would ensure adequate information for proper staging. Most urologists would agree that the removal of more nodal tissue results in more accurate staging and removal of undetected micrometastases. Thus, there is growing evidence that an extended dissection may provide a clinically meaningful benefit by conferring a survival advantage in both node-positive and node-negative patients.[10,11] A randomized trial of “standard” vs “extended” lymph node dissection is currently enrolling patients, and its results will be crucial in expanding our understanding of this key question.
The concept of lymph node density (ie, the number of positive nodes as a percentage of total nodes removed) reflects the quality of the nodal dissection and tumor burden. Lymph node density has been confirmed as a useful tool in predicting survival,[13,14] and data suggest that lymph node density performs better than the N status of TNM staging in risk stratification. Recently, the relevance of lymph node metastases and the benefits of lymphadenectomy have been nicely summarized in a collaborative review concluding that an “extended” lymph node dissection can be curative in patients with metastases or micrometastases and thus should be offered to all patients undergoing curative radical surgery.
Diversion of urine after removal of the bladder is a permanent quality-of-life issue after surgery. Today, there are three main categories of urinary diversion: a noncontinent cutaneous diversion (most commonly the ileal conduit), continent cutaneous diversions, and orthotopic reservoirs attached to native urethra (ie, neobladders).
An ileal conduit represents the simplest type of diversion and is associated with the fewest intraoperative and immediate postoperative complications. However, there are several prevalent associated long-term complications, including stomal stenosis, chronic or recurrent pyelonephritis, calculus disease, ureteroenteric anastomotic strictures, and renal deterioration. With regard to continent cutaneous diversions, the major long-term problem remains the provision of a durable continence mechanism.
Orthotopic neobladders have become more popular because they offer a number of theoretical advantages, including the ability to most nearly recreate normal voiding function, the ability to achieve continence with use of the native rhabdosphincter, avoidance of an abdominal stoma, easier urethral surveillance, a potentially lower urethral recurrence rate, and a superior body image.[15,16] However, there are risks of urinary incontinence, particularly nocturnal enuresis, of hypercontinence, and potentially of the need to catheterize and irrigate a pouch to drain excess mucus.
Various factors are important in the selection of patients for each type of diversion. To minimize the risk of urethral recurrence, investigators have found that patients undergoing orthotopic neobladder should not have bladder neck involvement, prostatic stromal invasion, or positive surgical margins on frozen section analysis. Additional considerations include patient preference and ability, mobility, manual dexterity, renal dysfunction, mentation, bowel availability, comorbidities, and life expectancy.
Disease recurrence rates are independent of urinary diversion type. Approximately 5% to 7% of men and 1% to 4% of women develop a urethral recurrence after the creation of an orthotopic neobladder.[18-20] Daytime continence rates remain greater than 95% for men and 90% for women, with nocturnal continence rates as high as 75% in men and 57% in women.[21,22] Some believe that an orthotopic neobladder improves quality of life compared with an ileal conduit, but most retrospective studies report no significant measurable difference.
Recently, investigators evaluated the utilization of ileal conduits and orthotopic neobladders in a large series of patients. They found a significant trend toward the use of ileal conduit urinary diversion in female patients, patients of advanced age, those with significant medical comorbidities, and those with locally advanced disease. However, orthotopic neobladders continue to be the most common urinary diversion in patients younger than 65 years.
RC remains one of the most challenging and complex surgeries in the urologic arsenal, for both the surgeon and the patient. Although operative mortality is low at 1%, overall complications are common, with an incidence near 40%. Early complications include pulmonary (atelectasis, pneumonia, pulmonary embolus, etc), gastrointestinal (ileus, small bowel obstruction, enterocutaneous fistula, etc), anastomotic (urine leak or obstruction), hemorrhagic, and wound-related effects (infection, dehiscence, and evisceration). Late complications include anastomotic site-related effects (strictures, stones, reflux), ostomy-related effects (hernias, prolapse), infections (pyelonephritis), and metabolic effects (acid/base disturbances, electrolyte disturbances, vitamin B12 deficiency).
Quality of care and the ability to control and improve outcomes continue to be important issues. We know that postoperative mortality after RC is inversely associated with the number of procedures performed. Many studies have suggested that high-volume providers have better infrastructure and more experience, which can lead to better outcomes. Volume is seen as a proxy for high quality of care; thus, centralization is believed to improve outcomes for patients undergoing RC. A recent meta-analysis confirmed this volume-outcome relationship. In particular, positive associations are seen between high-volume hospitals (and high-volume surgeons) and both mortality and survival. Furthermore, application of a fast-track clinical care pathway for patients undergoing RC reduces morbidity and improves recovery.
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA J Clin. 2010;60:277.
2. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconom. 2003;21:1315-30.
3. Isbarn H, Jeldres C, Zini L, et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol. 2009;182:70-7.
4. Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011;107:898-904.
5. Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 2011;12:137-43.
6. Lerner SP, Skinner DG, Lieskovsky G, et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993;149:758-64; discussion 64-5.
7. Poulsen AL, Horn T Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol. 1998;160:2015-9; discussion 20.
8. Karl A, Carroll PR, Gschwend JE, et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol. 2009;55:826-35.
9. Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002;167:1295-8.
10. Stein JP. The role of lymphadenectomy in patients undergoing radical cystectomy for bladder cancer. Curr Oncol Rep. 2007;9:213-21.
11. Dhar NB, Klein EA, Reuther AM, et al. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 2008;179:873-8; discussion 78.
12. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003;170:35-41.
13. Kassouf W, Agarwal PK, Herr HW, et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008;26:121-6.
14. May M, Herrmann E, Bolenz C, et al. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol. 2011;59:712-8.
15. Martins FE, Bennett CJ, Skinner DG. Options in replacement cystoplasty following radical cystectomy: high hopes or successful reality? J Urol. 1995;153:1363-72.
16. Bjerre BD, Johansen C, Steven K. Health-related quality of life after cystectomy: bladder substitution compared with ileal conduit diversion. A questionnaire survey. Br J Urol. 1995;75:200-5.
17. Hassan JM, Cookson MS, Smith JA, Chang SS. Urethral recurrence in patients following orthotopic urinary diversion. J Urol. 2004;172:1338-41.
18. Stein JP, Clark P, Miranda G, et al. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol. 2005;173:1163-8.
19. Studer UE, Burkhard FC, Schumacher M, et al. Twenty years experience with an ileal orthotopic low pressure bladder substitute--lessons to be learned. J Urol. 2006;176:161-6.
20. Gerharz EW, Månsson A, Hunt S, et al. Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol. 2005;174:1729-36.
21. Meyer J-P, Blick C, Arumainayagam N, et al. A three-centre experience of orthotopic neobladder reconstruction after radical cystectomy: revisiting the initial experience, and results in 104 patients. BJU Int. 2009;103:680-3.
22. Granberg CF, Boorjian SA, Crispen PL, et al. Functional and oncological outcomes after orthotopic neobladder reconstruction in women. BJU Int. 2008;102:1551-5.
23. Nagele U, Anastasiadis AG, Stenzl A, Kuczyk M. Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long-term oncological, functional, and quality of life results. World J Urol. 2011 Feb 5. [Epub ahead of print]
24. Lowrance WT, Rumohr JA, Clark PE, et al. Urinary diversion trends at a high volume, single American tertiary care center. J Urol. 2009;182:2369-74.
25. Hautmann RE, de Petriconi RC, Volkmer BG. 25 years of experience with 1,000 neobladders: long-term complications. J Urol. 2011;185:2207-12.
26. Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol. 1984;131:1069-72.
27. Goossens-Laan CA, Gooiker GA, van Gijn W, et al. A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: an update for the ongoing debate. Eur Urol. 2011;59:775-83.
28. Pruthi RS, Nielsen M, Smith A, et al. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg. 2010;210:93-9.
29. Stephenson AJ, Gill IS. Laparoscopic radical cystectomy for muscle-invasive bladder cancer: pathological and oncological outcomes. BJU Int. 2008;102:1296-301.
30. Chade DC, Laudone VP, Bochner BH, Parra RO. Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches. J Urol. 2010;183:862-69.
31. Wang GJ, Barocas DA, Raman JD, Scherr DS. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int. 2008;101:89-93.
32. Menon M, Hemal AK, Tewari A, et al. Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int. 2003;92:232-6.
33. Nix J, Smith A, Kurpad R, et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol. 2010;57:196-201.
34. Pruthi RS, Nielsen ME, Nix J, et al. Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. J Urol. 2010;183:510-4.
35. Hellenthal NJ, Hussain A, Andrews PE, et al. Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int. 2011;107:642-46.
36. Kauffman EC, Ng CK, Lee MM, et al. Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy. BJU Int. 2011;107:628-35.
37. Davis JW, Gaston K, Anderson R, et al. Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol. 2011;185:79-83.
38. Smith A, Kurpad R, Lal A, et al. Cost analysis of robotic versus open radical cystectomy for bladder cancer. J Urol. 2010;183:505-9.
39. Martin AD, Nunez RN, Castle EP. Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis. Urology. 2011;77:621-5.
40. Pruthi RS, Nix J, Mcrackan D, et al. Robotic-assisted laparoscopic intracorporeal urinary diversion. Eur Urol. 2010;57:1013-21.
41. Rozet F, Lesur G, Cathelineau X, et al. Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol. 2008;179:2170-4; discussion 74-5.
42. Simone G, Papalia R, Leonardo C, et al. Prostatic capsule and seminal vesicle-sparing cystectomy: improved functional results, inferior oncologic outcome. Urology. 2008;72:162-6.
43. Reese JH, Freiha FS, Gelb AB, et al. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol. 1992;147:92-5.
44. Montie JE, Wood DP, Pontes JE, et al. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer. 1989;63:381-5.
45. Kabalin JN, McNeal JE, Price HM, et al. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol. 1989;141:1091-4; discussion 93-4.
46. Revelo MP, Cookson MS, Chang SS, et al. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2008;179:S27-32.
47. Stein JP, Hautmann RE, Penson D, Skinner DG. Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. Urol Oncol. 2009;27:466-72.
48. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001;19:4005.
49. May M, Bastian PJ, Burger M, et al. Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder. BJU Int. 2011;108(8 Pt 2):E278-83.
50. Hollenbeck BK, Miller DC, Dunn RL, et al. The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urol Oncol. 2005;23:77-81.
51. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007;51:137-49; discussion 49-51.
52. Canter D, Long C, Kutikov A, et al. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int. 2011;107:58-62.
53. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999;354:533-40.
54. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171-7.
55. Grossman H, Natale R, Tangen C, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859.
56. Feifer A, Taylor J, Shouery M, et al. Multi-institutional quality of care initiative for non-metastatic muscle-invasive transitional cell carcinoma of the bladder: Phase 1. J Urol. 2011;185:e198.
57. David KA, Milowsky MI, Ritchey J, et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178:451-4.
58. Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer. 2011;117:276-82.
59. Collaboration ABCM-a. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927-34.
60. Svatek R, Shariat S, Lasky R, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010;16:4461.
61. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133:403-7.
62. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-77.
63. Sonpavde G, Ross R, Powles T, et al. Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008;101:937-43.
64. Volpe A, Racioppi M, D’agostino D, et al. Advanced bladder cancer: new agents and new approaches. A review. Urol Oncol. 2010 Sep 21. [Epub ahead of print]
65. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993;25:783-90.
66. Dunst J, Rödel C, Zietman A, et al. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol. 2001;20:24-32.
67. Fung CY, Shipley WU, Young RH, et al. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol. 1991;9:1533-42.
68. Ott OJ, Rödel C, Weiss C, et al. Radiochemotherapy for bladder cancer. Clin Oncol (R Coll Radiol). 2009;21:557-65.
69. Lagrange J-L, Bascoul-Mollevi C, Geoffrois L, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys. 2011;79:172-8.
70. Shipley WU, Zietman AL, Kaufman DS, et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates—the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol. 2005;15:36-41.
71. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11:2150-7.
72. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60:62-7; discussion 67-8.
73. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061-71.
74. Perdonà S, Autorino R, Damiano R, et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer. 2008;112:75-83.
75. Solsona E, Climent MA, Iborra I, et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol. 2009;55:911-9.
76. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14:119-26.
77. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16:3576-83.
78. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5:471-6.
79. Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73:833-7.
80. Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:665-72.
81. Rozan R, Albuisson E, Donnarieix D, et al. Interstitial iridium-192 for bladder cancer (a multicentric survey: 205 patients). Int J Radiat Oncol Biol Phys. 1992;24:469-77.
82. van Onna IEW, Oddens JR, Kok ET, et al. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol. 2009;56:113-21.
83. Van Der Steen-Banasik E, Ploeg M, Witjes JA, et al. Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study. Radiother Oncol. 2009;93:352-7.
84. van der Zee J, González D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet. 2000;355:1119-25.
85. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270-6.
86. Wittlinger M, Rödel CM, Weiss C, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol. 2009;93:358-63.
87. Chakravarti A, Winter K, Wu C-L, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62:309-17.
88. Pollack A, Wu CS, Czerniak B, et al. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res. 1997;3:1823-9.
89. Pollack A, Czerniak B, Zagars GK, et al. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1997;39:687-95.
90. Chyle V, Pollack A, Czerniak B, et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1996;35:281-7.
91. Moonen L, Ong F, Gallee M, et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys. 2001;49:1305-10.
92. Rödel C, Grabenbauer GG, Rödel F, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys. 2000;46:1213-21.
93. Garcia del Muro X, Condom E, Vigués F, et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer. 2004;100:1859-67.
94. Kawashima A, Nakayama M, Kakuta Y, et al. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res. 2011;17:2561-9.
95. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;
96. Paik M, Scolieri M, Brown S, et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;
97. Martingano P, Stacul F, Cavallaro M, et al. 64-Slice CT urography: 30 months of clinical experience. Radiol Med. 2010;115:920-35.
98. Wang L-J, Wong Y-C, Ng K-F, et al. Tumor characteristics of urothelial carcinoma on multidetector computerized tomography urography. J Urol. 2010;
99. El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol. 2009;19:1575-81.
100. Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging—accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009;251:112-21.
101. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55:761-9.
102. Lodde M, Lacombe L, Friede J, et al. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010;106:658-63.
103. Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27:4314-20.
104. Swinnen G, Maes A, Pottel H, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57:641-7.
105. Schöder H, Ong SC, Reuter VE, et al. Initial Results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imag Biol. 2011 Apr 14. [Epub ahead of print]
106. Golan S, Sopov V, Baniel J, Groshar D. Comparison of (11)C-choline with (18)F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol. 2011;186:436-41.